| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8268e39ce70ff2ad19742e2a21d5a90c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2db1eb4f46cbdcc40a8795011a1fe210 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-61
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-721
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 |
| filingDate |
2018-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69c13700d657edb1526f0d26e32429bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2290f3268af008283ac0266e52c2893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdb5fbd0d286a8b175daa3f6acb7e3bf |
| publicationDate |
2020-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3651750-A2 |
| titleOfInvention |
Methods and compositions for treating inflammation |
| abstract |
The invention provides methods and compositions for the treatment of neutrophil-mediated inflammation by targeting, in any combination, the pro-inflammatory MRP2 / HXA3 pathway and / or the anti-inflammatory P-gp / endocannabinoid pathway. and / or the anti-inflammatory MRP 1 / L-AMEND route, comprising administering to the subject a therapeutically effective amount of (a) one or more first compounds that inhibit the activity and / or level of one or more of a multidrug resistance protein 2 (MRP2) and heoxilin A3 (HXA3) synthase, and / or (b) one or more second compounds that increase the level and / or activity of one or more N -acylethanolamines (NAE) and / or (c) one or more third compounds which increase the level and / or activity of the multidrug resistance protein 1 (MRP1), the therapeutic amount of the first, second and third compounds reducing the neutrophil migration in the target tissue. |
| priorityDate |
2017-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |